In particular, cancer cells undergo reprogramming of the immune landscape upon inhibition of receptor tyrosine kinases, which provides the rationale for combining current bi‐EGF‐IT therapy with immunotherapy [42]. The gene discussed is NTRK1; the disease is cancer.